Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Total Current Liabilities (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Total Current Liabilities for 4 consecutive years, with $60.5 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities fell 17.6% to $60.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $60.5 million through Dec 2025, down 17.6% year-over-year, with the annual reading at $60.5 million for FY2025, 17.6% down from the prior year.
  • Total Current Liabilities for Q4 2025 was $60.5 million at Day One Biopharmaceuticals, up from $56.5 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $93.7 million in Q2 2024, with the low at $8.2 million in Q1 2022.
  • Average Total Current Liabilities over 4 years is $38.1 million, with a median of $29.7 million recorded in 2023.
  • The sharpest move saw Total Current Liabilities surged 282.29% in 2024, then tumbled 45.34% in 2025.
  • Over 4 years, Total Current Liabilities stood at $16.6 million in 2022, then surged by 77.6% to $29.5 million in 2023, then surged by 148.92% to $73.5 million in 2024, then fell by 17.6% to $60.5 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $60.5 million, $56.5 million, and $51.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.